Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report) Director David Benfer acquired 30,000 shares of the business's stock in a transaction on Tuesday, November 17th. The stock was acquired at an average price of $0.83 per share, with a total value of $24,900.00. Following the acquisition, the director owned 240,255 shares in the company, valued at $199,411.65. The trade was a 14.27% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Stereotaxis Stock Up 7.3%
STXS traded up $0.06 during trading on Wednesday, reaching $0.95. The company's stock had a trading volume of 900,994 shares, compared to its average volume of 991,370. The firm has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $1.61. Stereotaxis Inc. has a 1 year low of $0.80 and a 1 year high of $2.86. The company has a market cap of $94.80 million, a price-to-earnings ratio of -3.94 and a beta of 1.40.
Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $8.93 million for the quarter, compared to analyst estimates of $9.60 million. Stereotaxis had a negative return on equity of 144.02% and a negative net margin of 70.86%. As a group, equities analysts forecast that Stereotaxis Inc. will post -0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Stereotaxis
Several large investors have recently made changes to their positions in the stock. Integrity Alliance LLC. acquired a new position in Stereotaxis during the third quarter worth $860,000. Bank of New York Mellon Corp purchased a new position in shares of Stereotaxis during the second quarter worth $364,000. Sei Investments Co. grew its stake in shares of Stereotaxis by 108.9% in the first quarter. Sei Investments Co. now owns 518,884 shares of the company's stock valued at $955,000 after buying an additional 270,443 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Stereotaxis by 40.2% in the third quarter. Goldman Sachs Group Inc. now owns 329,420 shares of the company's stock valued at $405,000 after buying an additional 94,449 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of Stereotaxis in the third quarter valued at $60,000. 45.35% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages recently commented on STXS. Citizens Jmp reduced their price objective on Stereotaxis from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 27th. Citigroup reissued an "outperform" rating on shares of Stereotaxis in a research note on Thursday, August 27th. Finally, TD Cowen dropped their target price on Stereotaxis from $3.00 to $2.00 and set a "buy" rating for the company in a report on Wednesday, November 11th. Four equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $2.83.
Get Our Latest Analysis on Stereotaxis
Stereotaxis Company Profile
(
Get Free Report)
Stereotaxis develops robotic technologies for minimally invasive procedures, with a focus on treating heart rhythm disorders. Its systems are designed to help physicians guide catheters through blood vessels and within the heart during procedures such as cardiac ablation. The company's products include the Genesis Robotic Magnetic Navigation System, which uses externally controlled magnetic fields to steer compatible catheters, and the Odyssey platform for managing and displaying information in interventional procedure rooms.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stereotaxis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stereotaxis wasn't on the list.
While Stereotaxis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.